QPT Stock Overview
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Quest PharmaTech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.025 |
52 Week High | CA$0.10 |
52 Week Low | CA$0.02 |
Beta | 0.29 |
1 Month Change | 0% |
3 Month Change | -50.00% |
1 Year Change | -64.29% |
3 Year Change | -82.14% |
5 Year Change | -82.76% |
Change since IPO | -97.22% |
Recent News & Updates
Recent updates
Shareholder Returns
QPT | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | -1.8% | 0.2% |
1Y | -64.3% | -28.6% | 9.0% |
Return vs Industry: QPT underperformed the Canadian Biotechs industry which returned -27.7% over the past year.
Return vs Market: QPT underperformed the Canadian Market which returned 9.3% over the past year.
Price Volatility
QPT volatility | |
---|---|
QPT Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 13.5% |
Market Average Movement | 8.6% |
10% most volatile stocks in CA Market | 18.5% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: QPT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine QPT's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Madi Madiyalakan | https://www.questpharmatech.com |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Quest PharmaTech Inc. Fundamentals Summary
QPT fundamental statistics | |
---|---|
Market cap | CA$4.23m |
Earnings (TTM) | -CA$22.26m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs QPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QPT income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$22.26m |
Earnings | -CA$22.26m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 1.5% |
How did QPT perform over the long term?
See historical performance and comparison